1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...
After strong gains last year, biotech stocks are underperforming YTD despite a record wave of M&A activity fueled in part by ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This week's roundup of life ...
PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical ...
Now that a window has finally opened on Wall Street for biotech IPOs, a lineup of drug developers are taking their chances and jumping through. The latest to join the queue is Ambit Biosciences, which ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This week's life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results